← boardnext 2028-07
DYN
Dyne Therapeuticsdistress 4/10 · elevated risk$23.45+1%today-3% from 52w high
Lead: myotonic dystrophy type 1
Revenue
pre-revenue
Liquidity
$753M
Runway
1.7 yrs
Shares 1y
+0%
Price & events
+29.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.0%
1D
+3.2%
1W
+15.7%
1M
+24.1%
3M
+30.3%
6M
+150.0%
1Y
-46.7%
2Y
+20.1%
5Y
+23.4%
All
Overview
- Market Cap
- $3.35B
- Enterprise Value
- $2.75B
- Volume
- 175.49K
- 52 Week Range
- $8.28 – $24.29
- Total Shares
- 142.82M
- Float Shares
- 164.74M
- Short %
- 17.90%
- % Held by Insiders
- 0.28%
- % Held by Institutions
- 115.70%
- RVOL
- 0.07x
- Beta
- 1.06
Pipeline stages · 1 programs
Zeleciment Rostudirsen (DYNE-251)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-07 Estimated 50% readout ~2028-09-14 | Phase 3 | zeleciment basivarsen (DYNE-101)breakthroughfast trackorphanrare pediatric | Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease, Steinert | — | recruiting |
| 2029-07 Estimated 50% readout ~2029-08-15 | Phase 1/2 | DYNE-101breakthroughfast trackorphanrare pediatric | Myotonic Dystrophy Type 1 (DM1) | — | recruiting |
| 2029-11 Estimated 50% readout ~2029-12-16 | Phase 1/2 | DYNE-251breakthroughfast trackorphanrare pediatric | Duchenne Muscular Dystrophy (DMD) | — | active not recruiting |
| 2030-12 Estimated 50% readout ~2031-02-14 | Phase 3 | Zeleciment Rostudirsen (DYNE-251)breakthroughfast trackorphanrare pediatric | Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD), DMD, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Duchenne Type, Muscular Dystrophy, Duchenne and Becker Types, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Genetic Disease, Inborn, Genetic Disease, X-Linked, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neuromuscular Diseases (NMD) | — | recruiting |
Catalyst news & presentations · 15
- third quarter of 2027Guided 70%regulatory submissionFiled (NDA/BLA)zeleciment basivarsen · Potential BLA submission for U.S. Accelerated ApprovalSEC 8-K
- first quarter of 2027Guided 70%readoutPhase 1/2zeleciment basivarsen · Topline data from ACHIEVE registrational expansion cohortSEC 8-K
- late 2026Guided 55%regulatory submissionFiled (NDA/BLA)DYNE-101 · Potential U.S. Accelerated Approval submissionSEC 8-K
- 2026-07-27Estimated 45%earningsEarningsEarnings releaseyahoo
- early 2026regulatory submissionFiled (NDA/BLA)DYNE-251 · BLA submission for U.S. accelerated approvalSEC 8-K
- second quarter of 2026regulatory submissionFiled (NDA/BLA)zeleciment rostudirsen · Plans to submit BLA for U.S. Accelerated Approval.SEC 8-K
- second quarter of 2026trial initiationsecondaryPhase 3zeleciment rostudirsen · Plans to initiate global Phase 3 clinical trial.SEC 8-K
- mid-2026readoutPhase 2DYNE-101 · Data from Registrational Expansion Cohort to support U.S. Accelerated Approval submissionSEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 3DYNE-101 · Initiate confirmatory Phase 3 clinical trialSEC 8-K
- early 2026regulatory submissionFiled (NDA/BLA)DYNE-251 · Potential submission for U.S. Accelerated Approval for DYNE-251SEC 8-K
- late 2025readoutPhase 1/2DYNE-251 · Data from DELIVER Registrational Expansion Cohort expectedSEC 8-K
- fourth quarter of 2025enrollment completesecondaryPhase 2DYNE-101 · Complete enrollment in Registrational Expansion Cohort of ACHIEVE trialSEC 8-K
- mid-2025enrollment completesecondaryPhase 1/2DYNE-101 · Completion of enrollment of ACHIEVE Registrational Expansion CohortSEC 8-K
- first quarter of 2025enrollment completesecondaryPhase 1/2DYNE-251 · Completion of enrollment of DELIVER Registrational Expansion CohortSEC 8-K
- by the end of 2024readoutPhase 1/2DYNE-251 · Update on path to registration for DYNE-251SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $39 (+67% upside) · 15 analysts
- 2026-06-26TD CowenBuy
- 2026-05-15Evercore ISI GroupOutperform
- 2026-05-13BernsteinMarket Perform
- 2026-03-09Chardan CapitalBuy
- 2026-03-03Chardan CapitalBuy
- 2026-03-03Morgan StanleyOverweight
Competitors — myotonic dystrophy type 1
Recent news
- 2026-07-23Cantor Fitzgerald initiates Dyne Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
- 2026-07-22Form 424B5 Dyne Therapeutics Inc For: 22 July By Investing.com - Investing.com South Africa
- 2026-07-22Form 424B5 Dyne Therapeutics Inc For: 22 July By Investing.com - Investing.com Nigeria
- 2026-07-22Dyne Therapeutics Launches 18.3M-Share Offering at $20.50; Nets ~$352M, Greenshoe to $405M - TradingView
- 2026-07-22Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga
- 2026-07-22Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - Yahoo Finance
- 2026-07-22Dyne Therapeutics stock falls 9% after pricing stock offering By Investing.com - Investing.com Australia
- 2026-07-22Dyne Therapeutics stock falls 9% after pricing stock offering - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.